An anonymous reader shared this report from The Hill: A new study indicates the debilitating "brain fog" suffered by millions of long COVID patients is linked to changes in the brain, including inflammation and an impaired ability to rewire itself following COVID-19 infection. United Press International reported this week that the small-scale study, conducted by researchers at Corewell Health in Grand Rapids, Michigan, and Michigan State University, shows that altered levels of a pair of key brain chemicals could be the culprit. The study marks the first time doctors have been able to provide scientific proof that validates the experiences of the approximately 12 million COVID "long-haulers" in the U.S. who have reported neurological symptoms. Researchers looked at biomarkers in study participants and found that those complaining of brain fog had higher levels of an anti-inflammatory protein that is crucial to regulating a person's immune system, UPI reported. They also showed lower serum levels of nerve growth factor, a protein vital to the brain's plasticity... One of the biggest issues involving long COVID has been doctors' inability to find physical proof of the symptoms described by patients. The study has changed that, according to co-author Dr. Bengt Arnetz.

Read more of this story at Slashdot.

An anonymous reader quotes a report from the Associated Press: U.S. health officials on Friday endorsed the first blood test that can help diagnose Alzheimer's and identify patients who may benefit from drugs that can modestly slow the memory-destroying disease. The test can aid doctors in determining whether a patient's memory problems are due to Alzheimer's or a number of other medical conditions that can cause cognitive difficulties. The Food and Drug Administration cleared it for patients 55 and older who are showing early signs of the disease. The new test, from Fujirebio Diagnostics, Inc., identifies a sticky brain plaque, known as beta-amyloid, that is a key marker for Alzheimer's. Previously, the only FDA-approved methods for detecting amyloid were invasive tests of spinal fluid or expensive PET scans. The lower costs and convenience of a blood test could also help expand use of two new drugs, Leqembi and Kisunla, which have been shown to slightly slow the progression of Alzheimer's by clearing amyloid from the brain. Doctors are required to test patients for the plaque before prescribing the drugs, which require regular IV infusions. [...] A number of specialty hospitals and laboratories have already developed their own in-house tests for amyloid in recent years. But those tests aren't reviewed by the FDA and generally aren't covered by insurance. Doctors have also had little data to judge which tests are reliable and accurate, leading to an unregulated marketplace that some have called a "wild west." Several larger diagnostic and drug companies are also developing their own tests for FDA approval, including Roche, Eli Lilly and C2N Diagnostics. The tests can only be ordered by a doctor and aren't intended for people who don't yet have any symptoms.

Read more of this story at Slashdot.

Health authorities in densely-populated Hong Kong and Singapore have warned that Covid-19 cases are spiking, as a resurgent wave spreads through Asia. Bloomberg: The virus' activity in Hong Kong is now "quite high," Albert Au, head of the Communicable Disease Branch of the city's Center for Health Protection, told local media this week. The percentage of respiratory samples testing Covid-positive in Hong Kong recently reached its highest in a year. Severe cases -- including deaths -- also reached its highest level in about a year to 31 in the week through May 3, the center's data shows. While the resurgence is yet to match the infection peaks seen in the past two years, rising viral load found in sewage water and Covid-related medical consultations and hospitalizations suggest the virus is actively spreading in the city of over 7 million people. Rival financial hub Singapore is also on Covid alert. The city-state's health ministry released its first update on infection numbers in almost a year this month, as the estimated number of cases jumped 28% to 14,200 in the week through May 3 from the previous seven days while daily hospitalization rose around 30%. Singapore now only provides case updates when there is a noticeable spike.

Read more of this story at Slashdot.

Montana has passed a bill allowing licensed clinics to offer experimental medical treatments that haven't been approved by the FDA, provided the drugs have passed phase I safety trials. MIT Technology Review reports: The bill, which was passed by the state legislature on April 29 and is expected to be signed by Governor Greg Gianforte, essentially expands on existing Right to Try legislation in the state. But while that law was originally designed to allow terminally ill people to access experimental drugs, the new bill was drafted and lobbied for by people interested in extending human lifespans -- a group of longevity enthusiasts that includes scientists, libertarians, and influencers. These longevity enthusiasts are hoping Montana will serve as a test bed for opening up access to experimental drugs. [...] Supporters of the bill say it gives individuals the freedom to make choices about their own bodies. At the same event, bioethicist Jessica Flanigan of the University of Richmond said she was "optimistic" about the measure, because "it's great any time anybody is trying to give people back their medical autonomy." Ultimately, they hope that the new law will enable people to try unproven drugs that might help them live longer, make it easier for Americans to try experimental treatments without having to travel abroad, and potentially turn Montana into a medical tourism hub. But ethicists and legal scholars aren't as optimistic. "I hate it," bioethicist Alison Bateman-House of New York University says of the bill. She and others are worried about the ethics of promoting and selling unproven treatments -- and the risks of harm should something go wrong. [...] At any rate, the clinics are coming to Montana, says [Dylan Livingston, founder and CEO of the Alliance for Longevity Initiatives]. "We have half a dozen that are interested, and maybe two or three that are definitively going to set up shop out there." He won't name names, but he says some of the interested clinicians already have clinics in the US, while others are abroad." Mac Davis -- founder and CEO of Minicircle, the company that developed the controversial "anti-aging" gene therapy -- told MIT Technology Review he was "looking into it." "I think this can be an opportunity for America and Montana to really kind of corner the market when it comes to medical tourism," says Livingston. "There is no other place in the world with this sort of regulatory environment."

Read more of this story at Slashdot.

"The romantic partner of Theranos fraudster Elizabeth Holmes has launched a start-up that sounds eerily similar to the venture that landed his girlfriend behind bars," writes The Daily Beast. He's incorporated "Haemanthus" in Delaware a year and a half ago (though the company operates out of his neighborhood in Austin), according to the New York Times. Haemanthus appears to have around 10 employees. From The Daily Beast: California hotel heir Billy Evans' new company is a blood-testing firm that markets itself as "the future of diagnostics," offering "a radically new approach to health testing," according to The New York Times. In other words, exactly what Theranos said it would do. Holmes is even advising the start-up from the Texas prison where she is serving out an 11-year prison sentence for fraud, sources told NPR... Evans has managed to raise nearly $20 million in funds from both friends and established investors in Austin and San Francisco, according to the investor materials. The Times reports that Evan's company "plans to begin with testing pets for diseases before progressing to humans, according to two investors pitched on the company." And TechCrunch reminds readers that Elizabeth Holmes said in a recent interview "that she remains 'completely committed to my dream of making affordable healthcare solutions available to everyone.'"

Read more of this story at Slashdot.

Dr. Paul Offit, an expert on infectious disease and immunology, told the Guardian that "We're living in a post-herd-immunity world. I think the measles outbreak proves that. Measles — because it is the most contagious of the vaccine-preventable diseases, the most contagious human disease really — it is the first to come back." Three large outbreaks in Canada, Mexico and the US now account for the overwhelming majority of roughly 2,300 measles cases across the World Health Organization's six-country Americas region, according to the health authority's update this week. Risk of measles is considered high in the Americas, and has grown 11-fold compared with 2024. Only slightly behind, data released earlier this week from the European Centre for Disease Prevention and Control (ECDC) and WHO also noted that measles cases across Europe were up tenfold in 2024 compared to 2023. That data also indicated that the 2024 measles cases in Europe followed a seasonal pattern, which was not previously noted in 2021 through 2023. Of the European cases, which reportedly hit 35,212 for 2024, 87% were reported in Romania. The ECDC said the dip in vaccine rates has impacted the recent spike in measles, with only three countries, Hungary, Malta and Portugal, having coverage of 95% or more for both doses of the measles vaccine.

Read more of this story at Slashdot.

Long-time Slashdot reader piojo writes: Tim Friede, Wisconsin man, has been injecting himself with snake venom for 18 years to gain protection from his pet snakes. The antibodies he developed have formed two components of a three-part antivenom, which gives partial or total protection against 18 of 19 species of venomous snakes that were tested. Notably, the antivenom is ineffective against vipers. From Australia's public broadcaster ABC: The team's results have been published today in the journal Cell... The new antivenom described in the study is very different to traditional antivenoms, according to Peter Kwong, a biochemist at Columbia University and one of the study's authors. The scientists call their new antivenom "unparallel," according to the BBC, though the snake enthusiast (a former truck mechanic) had "initially wanted to build up his immunity to protect himself when handling snakes, documenting his exploits on YouTube." The team is trying to refine the antibodies further and see if adding a fourth component could lead to total protection against elapid snake venom... "Tim's antibodies are really quite extraordinary — he taught his immune system to get this very, very broad recognition," said Professor Peter Kwong [one of the researchers at Columbia University]. In a video interview, CNN shows footage of the man inducing snake bites (calling it "a classic do-not-try-this-at-home moment"). "I have a lot of notes in Excel files," he tells CNN, "where I hit these particular windows to where I know I can boost up before a bite." "I don't just take the bite, because that can kill you. I properly boost up, and methodically take notes, and weigh the venomes out very specifically..."

Read more of this story at Slashdot.

An anonymous reader quotes a report from The Hill: Daily exposure to certain chemicals used to manufacture household plastics may be connected to more than 356,000 cardiovascular-related deaths in 2018 alone, a new analysis has found. These chemicals, called phthalates, are present in products around the world but have particular popularity in the Middle East, South Asia, East Asia and the Pacific -- regions that collectively bore about 75 percent of the global death total, according to the research, published on Tuesday in the Lancet eBioMedicine. Phthalates, often used in personal care products, children's toys and food packaging and processing materials, are known to disrupt hormone function and have been linked to birth defects, infertility, learning disabilities and neurological disorders. The NYU Langone Health team focused in the analysis on a kind of phthalate called di-2-ethylhexyl phthalate (DEHP), which is used to make items like food containers and medical equipment softer and more flexible. Scientists have already shown that exposure to DEHP can trigger an overactive immune response in the heart's arteries, which over time can be linked to increased risk of heart attack or stroke. In the new analysis, the researchers estimated that DEHP exposure played a role in 356,238 global deaths in 2018, or nearly 13.5 percent of heart disease mortality among men and women ages 55 through 64. [...] These findings are in line with the team's previous research, which in 2021 determined that phthalates were connected to more than 50,000 premature deaths each year among older Americans -- most of whom succumbed to heart conditions. But this latest analysis is likely the first global estimate of cardiovascular mortality resulting from exposure to these environmental contaminants [...]. In a separate report from the New York Times, author Nina Agrawal highlights some of the caveats with the data. First of all, the study relies heavily on statistical modeling and assumptions, drawing from prior research that may include biases and confounding factors like diet or socioeconomic status. It also uses U.S.-based risk estimates that may not generalize globally and focuses only on one type of phthalate (DEHP). Additionally, as Agrawal points out, this is an observational study, showing correlation rather than causation. As such, more direct, long-term research is needed to clarify the true health impact of phthalate exposure.

Read more of this story at Slashdot.

An anonymous reader quotes a report from Business Insider: There is some microplastics in normal, healthy arteries," Dr. Ross Clark, a University of New Mexico medical researcher who led the study, told Business Insider before he presented his findings at the meeting of the American Heart Association in Baltimore on Tuesday. "But the amount that's there when they become diseased -- and become diseased with symptoms -- is really, really different," Clark said. Clark and his team measured microplastics and nanoplastics in the dangerous, fatty plaque that can build up in arteries, block blood flow, and cause strokes or heart attacks. Compared to the walls of healthy plaque-free arteries, plaque buildup had 16 times more plastic -- just in the people who didn't have symptoms. In people who had experienced stroke, mini-stroke, or vision loss, the plaque had 51 times more plastic. [...] To investigate why, Clark studied samples from 48 people's carotid arteries -- the pair of superhighways in your neck that channel blood to your brain. The difference in plastic quantities surprised him, but his team found another concerning trend, too. Cells in the plaque with lots of plastic showed different gene activity than those with low plastic. In the high-plastic environment, one group of immune cells had switched off a gene that's associated with turning off inflammation. Clark's team also found genetic differences in a group of stem cells thought to help prevent heart attacks and strokes by reducing inflammation and stabilizing plaque. "Could it be that microplastics are somehow altering their gene expression?" Clark said. He added that there's "lots more research needed to fully establish that, but at least it gives us a hint as to where to look." Ross, who specializes in the genetic mechanisms behind disease, agreed that more research is needed, but added that she thinks "these plastics are doing something with these plaques." Tracking microplastics in the human body is a new scientific endeavor as of the last couple years. It's not perfect. Clark's team heated the plaque samples to more than 1,000 degrees Fahrenheit to vaporize plastic polymers and break them down into smaller organic molecules, which can be identified and measured by their mass and other properties. Unfortunately, the lipids in plaque can break down into chemicals that look very similar to polyethylene, the most common plastic found in everything from plastic bags to car parts. "Because we know about this problem, we've taken a lot of steps to remove those lipids and confirm their removal, so that we're sure we're measuring polyethylene," Clark said. Still, he added, "it's a big limitation, and it should be acknowledged that these types of methodologies are continuously improving." "Almost all of what we know about microplastics in the human body, no matter where you look, can be summed up as: It's there, and we need to study further as to what it's doing, if anything," Clark said.

Read more of this story at Slashdot.

A new study projects that CT scans conducted in 2023 may result in around 103,000 future cancer cases in the U.S. due to low-dose ionizing radiation. "[I]t would put CT scans on par with other significant risk factors for cancer, like alcohol consumption, at least at a population level," reports ScienceAlert. From the report: At an individual level, the theoretical chance of developing cancer from a CT scan is thought to be very minimal, if it exists at all, and patients should not be scared of undergoing these tests if they are deemed medically necessary. However, the number of CT examinations performed each year in the US has increased by more than 30 percent since 2007, and researchers suggest that unwarranted tests are exposing the population to unnecessary radiation. [...] The anonymous data comes from 143 hospitals and outpatient facilities across the US, catalogued in the UCSF International CT Dose Registry. Using statistics from 2016 to 2022, researchers predicted 93 million CT examinations were carried out in 2023, on roughly 62 million patients. Based on the associated radiation risks, the team estimates that CT scans in 2023 may be tied to 103,000 future cancers. The findings have been published in JAMA Internal Medicine.

Read more of this story at Slashdot.

"More than three million children around the world are thought to have died in 2022 as a result of infections that are resistant to antibiotics," reports the BBC, citing a study by two leading experts in child health that used data from sources including the World Health Organization and the World Bank: Experts say this new study highlights a more than tenfold increase in AMR-related infections in children in just three years. The number could have been made worse by the impact of the Covid pandemic... The report's lead authors, Doctor Yanhong Jessika Hu of Murdoch Children's Research Institute in Australia and Professor Herb Harwell of the Clinton Health Access Initiative, point to a significant growth in the use of antibiotics that are meant to only be held back for the most serious infections. Between 2019 and 2021 the use of "watch antibiotics", drugs with a high risk of resistance, increased by 160% in South East Asia and 126% in Africa. Over the same period, "reserve antibiotics" — last-resort treatments for severe, multidrug-resistant infections — rose by 45% in South East Asia and 125% in Africa. The authors warn that if bacteria develop resistance to these antibiotics, there will be few, if any, alternatives for treating multidrug-resistant infections. "Antibiotics are ubiquitous around us," Professor Harwell warns in the article. "They end up in our food and the environment and so coming up with a single solution is not easy." The article also quotes a senior lecturer in microbiology at King's College London, who says the new study "marks a significant and alarming increase compared to previous data". "These findings should serve as a wake-up call for global health leaders. Without decisive action, AMR could undermine decades of progress in child health, particularly in the world's most vulnerable regions." Thanks to Slashdot reader Bruce66423 for sharing the article.

Read more of this story at Slashdot.

Scientists "demonstrated a promising step toward using a person's own immune cells to fight gastrointestinal cancers" at America's National Institutes of Health (or NIH), reports the Washington Post. But the results were published in Nature Medicine on Tuesday — "the same day the agency was hit with devastating layoffs..." The treatment approach is still early in its development; the personalized immunotherapy regimen shrank tumors in only about a quarter of the patients with colon, rectal and other GI cancers enrolled in a clinical trial. But a researcher who was not involved in the study called the results "remarkable" because they highlight a path to a frustratingly elusive goal in medicine — harnessing a person's own immune defenses to target common solid tumor cancers. Until now, cell-based immunotherapy has worked mainly on blood cancers, such as leukemia, but not the solid cancers that seed tumors in the breast, brain, lungs, pancreas and GI tract... But the progress arrives at a sad time for science — and for patients, said the leader of the work, NIH immunotherapy pioneer Steven Rosenberg. Two patients' treatments using the experimental therapy had to be delayed because NIH's capacity to make personalized cell therapies has been slowed by the firing of highly skilled staff and by purchasing slowdowns. Those occurred even before major layoffs took place Tuesday... The Department of Health and Human Services (HHS) responded to an email asking about clinical trial delays with a statement: "NIH and HHS are complying with President Trump's executive order." It's "a very exciting study," said Patrick Hwu, president of the Moffitt Cancer Center in Tampa. Finding ways to tailor this cell-based immunotherapy approach to common solid tumors that cause the vast majority of cancer deaths has remained a major scientific challenge... Rosenberg and colleagues first tried to create tumor infiltrating lymphocytes [or "TILs"] using the method that worked in melanoma for 18 patients with GI cancers that had spread. It failed completely. In a second iteration, his team sequenced the mutations present in each patient's tumor and used that information to sift out and expand the TILs that could home in on that patient's specific tumor cells. The results were far from a triumph, but provided a clue — this time, three of 39 patients' tumors shrank. In the last stage of the trial, the scientists added a drug called pembrolizumab that takes the brakes off immune cells. This time, eight of the 34 patients responded. "Right now, only a few labs in the country can do what they just did," Hwu said. While Rosenberg is already working "to refine and improve upon the results," he told the Post that two scientists involved in the specialized process of preparing the cells to treat patients were fired in the probationary purge. "We've had to slow down our work and delay the treatment of some patients...." And there's also dramatically fewer people now who can purchase research materials, which the Post says it "making it slower and more difficult to obtain supplies."

Read more of this story at Slashdot.

Longtime Slashdot reader backslashdot writes: Commentary, video, and a publication in this week's Nature Neuroscience herald a significant advance in brain-computer interface (BCI) technology, enabling speech by decoding electrical activity in the brain's sensorimotor cortex in real-time. Researchers from UC Berkeley and UCSF employed deep learning recurrent neural network transducer models to decode neural signals in 80-millisecond intervals, generating fluent, intelligible speech tailored to each participant's pre-injury voice. Unlike earlier methods that synthesized speech only after a full sentence was completed, this system can detect and vocalize words within just three seconds. It is accomplished via a 253-electrode array chip implant on the brain. Code and the dataset to replicate the main findings of this study are available in the Chang Lab's public GitHub repository.

Read more of this story at Slashdot.

Scientists in China successfully transplanted a genetically modified pig liver into a brain-dead patient, where it functioned for 10 days. The liver, modified to reduce immune rejection, produced key proteins and bile, showing compatibility and offering hope for future short-term xenotransplants. The Guardian reports: The surgery, at a Chinese hospital last year, is thought to mark the first time a pig liver has been transplanted into a human. It raises the prospect of pig livers serving as a "bridging organ" for patients on the waiting list for a transplant or to support liver function while their own organ regenerates. [...] The latest procedure was carried out in a 50-year-old man diagnosed with brain death after a severe head injury. The patient's own liver was intact and, in a surgery that took more than 10 hours, the organ taken from a genetically modified Bama miniature pig was plumbed into his blood supply as an additional liver. The pig had six genetic modifications aimed at preventing immune rejection. These included deactivating genes that contribute to the production of sugars on the surface of pig cells, which the human immune system attacks, and introducing genes that express human proteins to "humanize" the liver. After the transplant, the pig liver showed signs of functioning, including producing bile, which helps break down fats in the digestive system, and porcine albumin, a blood protein. The team behind the advance, described in the journal Nature, said it was not clear whether the liver would have been able to fully support the patient, given that he had an existing liver and because the liver was removed after 10 days at the request of his family.

Read more of this story at Slashdot.

NPR reports on research "into whether our defenses built up from past flu seasons can offer any protection against H5N1 bird flu." So far, the findings offer some reassurance. Antibodies and other players in the immune system may buffer the worst consequences of bird flu, at least to some degree. "There's certainly preexisting immunity," says Florian Krammer, a virologist at Mount Sinai's Icahn School of Medicine who is involved in some of the new studies. "That's very likely not going to protect us as a population from a new pandemic, but it might give us some protection against severe disease." This protection is based on shared traits between bird flu and types of seasonal flu that have circulated among us. Certain segments of the population, namely older people, may be particularly well-primed because of flu infections during early childhood. Of course, there are caveats. "While this is a bit of a silver lining, it doesn't mean we should all feel safe," says Seema Lakdawala, a virologist at Emory University's School of Medicine whose lab is probing this question. For one thing, the studies can't be done on people. The conclusions are based on animal models and blood tests that measure the immune response. And how this holds up for an individual is expected to vary considerably, depending on their own immune history, underlying health conditions and other factors. But for now, influenza researchers speculate this may be one reason most people who've caught bird flu over the past year have not fallen severely ill.... Research published this month is encouraging. By analyzing blood samples from close to 160 people, a team at the University of Pennsylvania and the University of Chicago were able to show that people born roughly before 1965 had higher levels of antibodies — proteins that bind to parts of the virus — which cross-react to the current strain of bird flu. This week U.S. federal officials also "announced funding for avian influenza research projects, including money for new vaccine projects and potential treatments," the Guardian report. The head of America's agriculture department said it would invest $100 million, as part of a larger $1 billion initiative to fight bird flu and stop rising egg prices, according to the nonprofit news site Iowa Capital Dispatch.

Read more of this story at Slashdot.

A newly FDA-approved form of adaptive deep-brain stimulation (DBS) for Parkinson's disease adjusts electrical stimulation in real time based on an individual's brain signals, improving symptom control and reducing medication dependence. Scientific American: For decades, Keith Krehbiel took high doses of medications with a debilitating side effect -- severe nausea -- following his diagnosis with early-onset Parkinson's disease at age 42 in 1997. When each dose wore off, he experienced dyskinesia -- involuntary, repetitive muscle movements. In his case, this consisted of head bobbing and weaving. Krehbiel is among one million Americans who live with this progressive neurological disorder, which causes slowed movements, tremors and balance problems. But soon after surgery to implant electrodes into specific areas of his brain in 2020, his life dramatically improved. "My tremor went away almost entirely," says Krehbiel, now age 70 and a professor emeritus of political science at the Stanford Graduate School of Business, whose Parkinson's symptoms began at age 40 and were initially misdiagnosed as repetitive stress injury from computer use. "I reduced my Parkinson's meds by more than two thirds," he adds. "And I no longer have a sensation of a foggy brain, nor nausea or dyskinesia." Krehbiel was the first participant to enroll in a clinical trial testing a new form of deep-brain stimulation (DBS), a technology that gained approval from the U.S. Food and Drug Administration for Parkinson's tremor and essential tremor in 1997 (it was later approved for other symptoms and conditions). The new adaptive system adjusts stimulation levels automatically based on the person's individual brain signals. In late February it received FDA approval for Parkinson's disease "based on results of the international multicenter trial, which involved participants at 10 sites across a total of four countries -- the U.S., the Netherlands, Canada and France. This technology is suitable for anyone with Parkinson's, not just individuals in clinical trials, says Helen Bronte-Stewart, the recent trial's global lead investigator and a neurologist specializing in movement disorders at Stanford Medicine. "Like a cardiac pacemaker that responds to the rhythms of the heart, adaptive deep-brain stimulation uses a person's individual brain signals to control the electric pulses it delivers," Bronte-Stewart says. "This makes it more personalized, precise and efficient than older DBS methods." "Traditional DBS delivers constant stimulation, which doesn't always match the fluctuating symptoms of Parkinson's disease," adds neurologist Todd Herrington, another of the trial's investigators and director of the deep-brain stimulation program at Massachusetts General Hospital. With adaptive DBS, "the goal is to adjust stimulation in real time to provide more effective symptom control, fewer side effects and improved patient quality of life." Current FDA approval of this adaptive system is for the treatment of Parkinson's only, not essential tremor, dystonia (a neurological disorder that causes excessive, repetitive and involuntary muscle contractions) or epilepsy, which still rely on traditional, continuous DBS, Herrington says.

Read more of this story at Slashdot.